[1. Gutierrez J, Calvete J, Habib A, Harrison R, Williams D, Warrell D: Snakebite envenoming. Nature Reviews Disease Primers 2017, 3:17063.10.1038/nrdp.2017.63]Search in Google Scholar
[2. Chippaux JP: Snake-bites: appraisal of the global situation. Bulletin of the WHO 1998, 76(5): 515-524.]Search in Google Scholar
[3. Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, Savioli L, Lalloo DG, de Silva HJ: The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of Envenoming and Deaths. PLoS ONE 2008, 5:e218.10.1371/journal.pmed.0050218]Search in Google Scholar
[4. World Health Organization (WHO): Venomous snakes distribution and species risk categories. Geneva, Switzerland: WHO Press; 2010a. [http://apps.who.int/bloodproducts/snakeantivenoms/database/].]Search in Google Scholar
[5. Lamb T, Haro L, Lonati D, Brvar M, Eddleston M: Antivenom for European Vipera species envenoming. Clinical Toxicology 2017, 55(6):557-568.10.1080/15563650.2017.1300261]Search in Google Scholar
[6. Moroz-Perlmutter C, Goldblum N, de Vries A, Gitter S: Detoxification of snake venoms and venom fractions by formaldehyde. Proceedings of the Society for Experimental Biology and Medicine 1963, 112:595–598.10.3181/00379727-112-28113]Search in Google Scholar
[7. World Health Organization (WHO): Guidelines for the production, control and regulation of snake antivenom immunoglobulins. Geneva, Switzerland: WHO Press; 2018. [http://www.who.int/bloodproducts/snake_antivenoms/snakeantivenomguide/en/].]Search in Google Scholar
[8. World Health Organization (WHO): Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins. Geneva, Switzerland: WHO Press; 2010b. [http://www.who.int/bloodproducts/snake_antivenoms/snakeantivenomguideline.pdf]]Search in Google Scholar
[9. Freitas TV, Fortes-Dias CL, Diniz CR, Velarde DT, Freitas CF: Immunization of horses with Crotalus durissus terrificus (South American rattlesnake) venom. A comparison of four different procedures. Brazilian Journal of Medical and Biological Research 1991, 24:281–290.]Search in Google Scholar
[10. Pratanaphon R, Akesowan S, Khow O, Sriprapat S, Ratanabanangkoon K: Production of highly potent horse antivenom against the Thai cobra (Naja kaouthia). Vaccine 1997, 15:1523–1528.10.1016/S0264-410X(97)00098-4]Search in Google Scholar
[11. Chotwiwatthanakun C, Pratanaphon R, Akesowan S, Sriprapat S, Ratanabanangkoon K: Production of potent polyvalent antivenom against three elapid venoms using a low dose, low volume, multi-site immunization protocol. Toxicon 2001, 39:1487–1494.10.1016/S0041-0101(01)00108-8]Search in Google Scholar
[12. Sriprapat S, Aeksowan S, Sapsutthipas S, Chotwiwatthanakun C, Suttijitpaisal P, Pratanaphon R, Khow O, Sitprija V, Ratanabanangkoon K: The impact of a low dose, low volume, multi-site ation on the production of therapeutic antivenoms in Thailand. Toxicon 2003, 41:57–64.10.1016/S0041-0101(02)00209-X]Search in Google Scholar
[13. Sapsutthipas S, Leong PK, Akesowan S, Pratanaphon R, Tan NH, Ratanabanangkoon K: Effective equine imunization protocol for production of potent poly-specific antisera against Calloselasma rhodostoma, Cryptelytrops albolabris and Daboia siamensis. PLoS Neglected Tropical Diseasess 2015, 9:e0003609.10.1371/journal.pntd.0003609436104625774998]Search in Google Scholar
[14. Artigas RS, Cruz AM, Martin OP, Baptista LA, Valdes DC, Pupo OM: Obtention of tetanus antitoxin hyperimmune sera in equines. International Journal of Current Research 2016, 8:36248-36253.]Search in Google Scholar
[15. Shantavasinkul P, Tantawichien T, Jaijaroensup W, Lertjarutorn S, Banjongkasaena A, Wilde H, Sitprija V. A 4-Site, Single-Visit Intradermal Postexposure Prophylaxis Regimen for Previously Vaccinated Patients: Experiences with 15000 Patients. Clinical Infectious Diseases 2010, 51:1070-1072.10.1086/65658520887204]Search in Google Scholar
[16. Council of Europe: European viper venom antiserum. In: European Pharmacopoeia 8.0. Strasbourg, France; 2014, 1033.]Search in Google Scholar
[17. Halder M: Three Rs potential in the development and quality control of immunobiologicals. Alternatives to Animal Experimentation 2001, 18(Suppl. 1):13-47.]Search in Google Scholar
[18. Russell WMS, Burch RL: The Principles of Humane Experimental Technique. London, United Kingdom: Methuen, 1959.]Search in Google Scholar
[19. Zivkovic I, Rajnpreht I, Minic R, Mitic K, Aleksic I, Kadric J, Petrusic V: Characterization of Intor:Swiss albino mice adopted in the Institute of Virology, Vaccines and Sera – Torlak, Belgrade in the early twentieth century. Acta veterinaria – Belgrade 2016, 66(3):279-293.10.1515/acve-2016-0025]Search in Google Scholar
[20. European Medicines Agency (EMA): Note for guidance on validation of analytical procedures: text and methodology. ICH Harmonised Tripartite Guideline 2005. [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf].]Search in Google Scholar
[21. Pullen GR, Fitzgerald MG, Hosking CS: Antibody avidity determination by ELISA using thiocyanate elution. Journal Immunological Methods 1986, 86:83–87.10.1016/0022-1759(86)90268-1]Search in Google Scholar
[22. Russell FE. Snake venom immunology: historical and practical considerations. Journal of Toxicology: Toxin Reviews 1988, 7:1-82.10.3109/15569548809059725]Search in Google Scholar
[23. Kalyan kumar B, Nanda1 S, Venkateshwarlu1 P, Kiran kumarY, Jadhav RT: Antisnake Venom Serum (ASVS). International Journal on Pharmaceutical and Biomedical Research 2010, 1(3): 76-89.]Search in Google Scholar
[24. Murray A, Lawrence GP: How should the repeatability of clinical measurements be analysed? An assessment of analysis techniques with data from cardiovascular autonomic function tests. Quarterly Journal of Medicine 1993, 86:831-836.]Search in Google Scholar
[25. Biddlecombe RA, Law B: Validation of an immunoassay. In: Immunoassay: a Practical Guide. London, United Kingdom: Taylor & Francis Group; 1996, 179-192.]Search in Google Scholar
[26. De Roodt A, Dolab JA, Segre L, Simoncini C, Hajos SE, Fernandez T, Dokmetjian JC, Litwin S, Accattoli C, Vidal JC: The Immunochemical Reactivity and Neutralizing Capacity of Polyvalent Vipera (European) Antivenom on Enzymatic and Toxic Activities in the Venoms of Crotalids from Argentina. Journal of Venomous Animals and Toxins 1999, 5:67-83.10.1590/S0104-79301999000100006]Search in Google Scholar
[27. Casewell NR, Al-Abdulla I, Smith D, Coxon R, Landon J: Immunological Cross-Reactivity and Neutralisation of European Viper Venoms with the Monospecific Vipera berus Antivenom ViperaTAb. Toxins (Basel) 2014, 6:2471-2482.10.3390/toxins6082471]Search in Google Scholar
[28. Stills HF Jr: Adjuvants and Antibody Production: Dispelling the Myths Associated withFreund’s Complete and Other Adjuvants. ILAR Journal 2005, 46:280-294.10.1093/ilar.46.3.280]Search in Google Scholar
[29. Poulsen TR, Jensen A, Haurum JS, Andersen PS: Limits for Antibody Affinity Maturation and Repertoire Diversification in Hypervaccinated Humans. Journal of Immunology 2011, 187:4229-4235.10.4049/jimmunol.1000928]Search in Google Scholar
[30. Maede Y, Inaba M, Amano Y, Murase T, Goto I, Itakura C: Cryoglobulinemia in a Horse. The Journal of Veterinary Medical Science 1991, 53:379-383.10.1292/jvms.53.379]Search in Google Scholar
[31. Theakston RDG, Reid HA: Enzyme linked immunosorbent assay (ELISA) in assessing antivenom potency. Toxicon 1979, 17:511-515.10.1016/0041-0101(79)90284-8]Search in Google Scholar
[32. Rungsiwongse J, Ratanabamamgkoon K: Development of an ELISA to assess the potency of horse therapeutic antivenom against Thai cobra venom. Journal of Immunological Methods 1991, 136:37-43.10.1016/0022-1759(91)90247-D]Search in Google Scholar
[33. Ibrahim NM, Farid NM: Comparison between Two In Vitro ELISA-Based Assays in the Determination of Antivenom Potency. Journal of Applied Sciences Research 2009, 5:1223-1229.]Search in Google Scholar
[34. Georgieva D, Risch M, Kardas A, Buck F, von Bergen M, Betzel C: Comparative Analysis of the Venom Proteomes of Vipera ammodytes ammodytes and Vipera ammodytes meridionalis. Journal of Proteome Research 2008, 7:866–886.10.1021/pr070376c18257516]Search in Google Scholar
[35. Halassy B, Brgles M, Habjanec L, Lang Balija M, Kurtovic T, Marchetti-Deschmann M, Krizaj I, Allmaier G: Intraspecies variability in Vipera ammodytes ammodytes venom related to its toxicity and immunogenic potential. Comparative Biochemistry and Physiology, Part C 2011, 153:223–230.10.1016/j.cbpc.2010.10.007]Search in Google Scholar
[36. Halassy B, Habjanec L, Brgles M, Lang Balija M, Leonardi A, Kovacic L, Prijatelj P, Tomasic J, Krizaj I: The role of antibodies specific for toxic sPLA2s and haemorrhagins in neutralizing potential of antisera raised against Vipera ammodytes ammodytes venom. Comparative Biochemistry and Physiology - Part C: Toxicology & Pharmacology 2008, 148:178-83.10.1016/j.cbpc.2008.05.005]Search in Google Scholar
[37. Theakson RDG, Warrell DA, Griffiths E: Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003, 41: 541-557.10.1016/S0041-0101(02)00393-8]Search in Google Scholar